Showing 4761-4770 of 5623 results for "".
- ReFocus Eye Health Acquires OptiCare Eye Health & Vision Centershttps://modernod.com/news/refocus-eye-health-acquires-opticare-eye-health-vision-centers/2478105/ReFocus Eye Health has announced the acquisition of OptiCare Eye Health & Vision Centers. Terms of the deal were not disclosed. “We couldn’t be more excited about the surgeons and staff of OptiCare becoming part of the ReFocus family,”
- MicroOptx Completes Patient Enrollment in Initial Phase of US Pivotal Trial for the Beacon Aqueous Microshunthttps://modernod.com/news/microoptx-completes-patient-enrollment-in-initial-phase-of-us-pivotal-trial-for-the-beacon-aqueous-microshunt/2478098/MicroOptx announced the completion of enrollment in the initial phase of the Beacon Study. This is the FDA investigational device exemption (IDE) clinical trial of the Beacon Aqueous Microshunt. Study participants treated during the initial phase of the interventional, single-arm, open label, mul
- TearLab Appoints Adam Szaronos as Chief Commercial Officerhttps://modernod.com/news/tearlab-appoints-adam-szaronos-as-chief-commercial-officer/2478094/TearLab announced the appointment of Adam Szaronos to the position of Chief Commercial Officer (CCO). Mr. Szaronos brings a wealth of experience gained over the past 15 years and will help guide the evolution of TearLab as it
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-4d-110-by-intravitreal-injection-for-the-treatment-of-choroideremia/2478092/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1 clinical trial of 4D-110, a Roche-licensed product candidate, delivered by a single intravitreal injection for Choroideremia. Choroideremia is a blinding and currently untreatable X-linked inher
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmology for 19th Timehttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-19th-time/2478089/Bascom Palmer Eye Institute of the University of Miami Health System has been ranked again as the nation’s best in ophthalmology by U.S News & World Report. This year marks the 19th time, and the 17th consecutive year, that
- Pfizer, BioNTech Begin Phase 2/3 Coronavirus Vaccine Studyhttps://modernod.com/news/pfizer-biontech-pick-bnt162b2-to-advance-into-phase-2-3-coronavirus-vaccine-study/2478084/Pfizer and partner BioNTech said they have decided to advance the nucleoside-modified mRNA vaccine candidate BNT162b2 into phase 2/3 testing. The vaccine, to be trialed at the 30-mcg dose as part of a two-dose regimen, encodes for an optimized SARS-CoV-2 full-length spike glycoprotein, which the
- COVID-19 Vaccine Candidate Heads To Widespread Testing In U.S.https://modernod.com/news/covid-19-vaccine-candidate-heads-to-widespread-testing-in-u-s/2478083/The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday, according to an NPR
- New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercepthttps://modernod.com/news/new-novartis-analysis-shows-wet-amd-patients-achieved-sustained-fluid-control-faster-with-beovu-versus-aflibercept/2478080/Novartis announced results of a new post-hoc analysis of Beovu (brolucizumab) phase 3 HAWK and HARRIER pivotal trials demonstrating faster sustainable fluid control when compared with aflibercept in patients with wet
- jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosahttps://modernod.com/news/jcyte-announces-phase-2b-results-of-jcell-therapy-in-retinitis-pigmentosa/2478078/jCyte Inc. announced promising results from a phase 2b clinical trial of jCell in retinitis pigmentosa (RP), irrespective of genetic subtype. jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addi
- Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 Phase 2 Clinical Trial in Patients with Macular Edema Due to RVOhttps://modernod.com/news/aerie-pharmaceuticals-reports-positive-topline-results-for-ar-1105-phase-2-clinical-trial-in-patients-with-macular-edema-due-to-rvo/2478079/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating AR-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion. AR-1105 Phase 2 Highlights